XNAS
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its investigational new drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder. The company operates as one operating segment with a focus on drug development for addiction and related disorders.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | Q1 2026 | -2.15 | -1.48 | +31.16% | $0 | ✅ Beat | +0.70% | -3.50% | — |
| 2026-03-06 | Q4 2025 | -2.12 | -11.48 | -441.51% | $0 | ❌ Miss | -2.03% | +7.10% | -4.37% |
| 2025-11-13 |
| Q3 2025 |
| -0.11 |
| -0.08 |
| +27.27% |
| $0 |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-13 | Q2 2025 | -0.22 | -0.18 | +18.18% | $0 | ✅ Beat | -2.27% | -7.00% | -12.50% |
| 2025-03-04 | Q4 2024 | -0.33 | -0.15 | +54.55% | $0 | ✅ Beat | +2.65% | -15.50% | -10.04% |
| 2024-11-13 | Q3 2024 | -0.41 | -0.38 | +7.32% | $0 | ✅ Beat | +15.04% | +2.93% | +9.99% |
| 2024-08-13 | Q2 2024 | — | -0.59 | — | $0 | — | -0.96% | +0.06% | +11.85% |
| 2024-05-14 | Q1 2024 | -0.35 | -2.19 | -525.71% | $0 | ❌ Miss | -1.39% | -2.78% | -9.86% |
Showing last 8 quarters.